NMTT Acquires Pandora .

For love, Tan Sri Dr A.Yuhao invests heavily in mergers and acquisitions new anti-COVID-19 technology brings good news to people with new crown sequelae

As the new coronavirus continues to mutate around the world, the infection rate is gradually increasing, the number of confirmed cases continues to rise, and the sequelae of infected persons are complex and changeable. A large number of domestic and international literatures report nearly 200 sequelae of the new coronavirus infection, the more serious ones are brain aging, brain damage, genital damage, and even more terrifying infections in people with basic diseases such as hypertension, hyperglycemia, hyperlipidemia, and chronic obstructive pulmonary disease. The risk of cardiovascular and cerebrovascular diseases after the new coronavirus has increased by nearly 70% on the original basis. A recent study conducted by The University of Queensland showed that about 20% of hospitalized patients with COVID-19 developed acute kidney injury (AKI). . However, so far, there are very few researches and effective measures to alleviate, diagnose, treat or prevent the sequelae of COVID-19 infection. This may be a new challenge for humanity after the COVID-19 pandemic.

Figure 1. Diagram of the mechanism of acute kidney injury (AKI) in patients with COVID-19

Source: DOI: 10.1007/s40620-020-00851-9

When human beings enter the era of active drugs, this may be one of the effective methods and paths for human beings to establish defense and treat the sequelae of new coronavirus and viral infection, as well as for specific people who cannot be vaccinated. Shenzhen Shuangke Biotechnology Co., Ltd., China has developed the "independent original technology with "radar + GPS" spot type KK-Umh-NK01V" for the sequelae of COVID-19 infection. The technology has strong targeting recognition ability, high purity and activity, the ability to release the main factors of killing viruses and other biological efficacy, and based on its independent series of innovative technologies, it can effectively realize that the "active drug" can be stored in vitro at room temperature for no less than 72 hours without affecting its activity and efficacy, effectively solving the "active drug". The problem of "drug" transportation and the expansion of its service radius, at the same time, based on the realization of the ability to multiply nearly 10,000 times, the comprehensive cost has been effectively reduced, the production capacity has been increased, and more people with indications can enjoy it. Now Malaysia Pandora Biotechnology. Co. Ltd Pandora Biotechnology Group, as the authorized cooperative enterprise of Shenzhen Shuangke Biotechnology Co. Ltd. in regions other than China, is responsible for the application of the technology to the US FDA-IND and the development of clinical trials, transformation applications and its exclusive enterprise platform for industrialization.

Figure 2. Chief scientist Dr. ZHOU is discussing with the team the immune killing mechanism for the prevention and control of the new coronavirus.

Image source: Used with permission from Shenzhen Shuangke Biotechnology Co., Ltd. China

In October last year, Tan Sri Dr A.Yuhao used a set of NKG2D-CTL-V targeting technology system independently created by Shenzhen Shuangke Biotechnology Co. Ltd, China and the world's leading target for hepatitis virus under the recommendation of a friend. Three months later Re-examination of viral DNA, liver and kidney function, immune function and other data showed that the virus was completely eliminated, and the functional antiviral ability was remodeled, the liver and kidney functions returned to normal, and the body's resistance was significantly improved. What is even more surprising is that due to perennial smoking the resulting subclinical diseases such as pulmonary inflammation and emphysema were also effectively suppressed and well repaired. In the process, Tan Sri Dr A. Yuhao learned that the Institute of Medical Research is researching [carrying” for the sequelae of COVID-19 infection. Radar + GPS” spot type KK-Umh-NK01V technology], after learning the real world data of his research, he highly appreciates and has a strong interest.

(Image credit: Courtesy of the University of Lincoln Photographer)

In view of the fact that in recent years, Tan Sri Dr. Yuhao has established scientific and technological research centers in Malaysia and West Africa, the two sides have reached a high degree of consensus in many aspects during the exchange process, and the two sides have deep complementary advantages in resources, markets, capital, technology, etc., Immediately, the two parties reached a consensus on cooperation.

Figure 3: Tan Sri Dr Yuhao won the Malaysia Charity Festival Award in 2019. The picture shows the award speech.

Image source: Provided by the organizer of the Public Welfare Festival

To this end, Tan Sri Dr A. Yuhao asked NMTT, a biotech company listed on the US OTC, to formally propose a merger and acquisition intention to Pandora Biotechnology. Co. Ltd Malaysia. After several rounds of friendly discussions, the two parties reached a merger agreement and has On May 18, 2022, an M&A agreement was officially signed to fully acquire Pandora Biotech Malaysia with a market value of several hundred million US dollars. It has now started the relevant preparations for the IND application in the FDA in accordance with the industry management department for the cooperation project. Southeast Asia and other countries carry out clinical experiments, translational applications and industrialization development, and it may become the first Asian biotechnology company listed in the United States with the industrialization of new, personalized, targeted, and off-the-shelf immune cell therapy technology. The results will bring the application of self-developed new immune cell technology to Asians, instead of relying on Europe and the United States as in the past. We also wish the success of this project to bring the dawn of a normal and high-quality life for the global patients with COVID-19 sequelae and tumors.

Image source: provided by the photographer at the signing ceremony, the signing ceremony of the M&A agreement was completed on May 18, Tan Sri Dr A.Yuhao, Chief Scientist Dr. ZHOU